TrialCardiovascular diabetology2019

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.

Benedetta Maria Bonora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.